Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Icahn School of Medicine at Mount Sinai)
- Development stage
- Unknown
- Lead developer
- Maia Kayal
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Oral
01
Overview
Fecal microbiota transplant (FMT) is an investigational biologic therapy being evaluated for the treatment of chronic pouchitis in a Phase 1 clinical trial (NCT05829109). The study is led by Dr. Maia Kayal at the Icahn School of Medicine at Mount Sinai. This therapy involves the administration of fecal microbiota collected from healthy donors. A novel aspect of this particular study is that the donors are individuals with healthy ileal pouches, as opposed to donors with intact colons, which has been the standard in previous studies. The primary goal is to correct the dysbiosis (imbalance of gut bacteria) within the recipient's inflamed pouch by introducing a healthy pouch microbiome, thereby reducing inflammation associated with chronic pouchitis. Chronic pouchitis is an inflammatory condition that can affect patients with ulcerative colitis who have undergone a total proctocolectomy with ileal pouch-anal anastomosis.
- Other names
- Fecal microbiota transplantationFMTHealthy to Inflamed Pouch FMT
Beyond the preview
Go deeper on fecal microbiota transplant (Icahn School of Medicine at Mount Sinai).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Icahn School of Medicine at Mount Sinai).